Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature

Zhang, Xi; Liu, Yang; Zhang, Zhen; Tan, Juan; Ou, Hao; Li, Jie; Song, Zewen

doi:10.3389/fcell.2021.649265

Cited by 6 publications

(5 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since its introduction as a broad-spectrum anti-tumor-targeted drug, anlotinib has made significant progress in the treatment of cancers and has played a role in a wide range of malignancies (34)(35)(36)(37). Zhang et al discovered that anlotinib inhibited PC cell proliferation while inducing apoptosis (38). Yang et al demonstrated that anlotinib killed PC cells both in vitro and in vivo (39).…”

Section: Discussionmentioning

confidence: 99%

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

Zhan

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundAnlotinib may boost the efficacy of pancreatic cancer (PC) treatment if timely added to the GS regimen (Gemcitabine, Tegafur-gimeracil-oteracil potassium); however, no data has been published. This study evaluated the safety and efficacy of anlotinib in combination with the GS regimen(hereafter referred to as the A+GS regimen) in the first-line treatment of patients with unresectable or metastatic PC.MethodsPatients with unresectable or metastatic PC treated at Yueyang Central Hospital and Yueyang People’s Hospital between October 2018 and June 2022 were enrolled in this retrospective real-world investigation. Treatment efficacy was evaluated based on the overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and objective response rate (ORR), while the treatment safety was assessed by the frequency of major adverse events (AEs).ResultsSeventy-one patients were included in this study, 41 in the GS group and 30 in the A+GS group. The A+GS group had a longer mPFS than the GS group (12.0 months (95% CI, 6.0–18.0) and 6.0 months (95% CI, 3.0–8.1)), respectively (P = 0.005). mOS was longer in the GS+A group) when compared with the GS group (17.0 months (95%CI, 14.0–20.0) and 10.0 months (95% CI, 7.5–12.5)), respectively (P = 0.018). The GS+A group had higher ORR (50.0% vs 26.8%, P = 0.045) and DCR (83.3% vs 58.5%, P = 0.026). Furthermore, there were no grade 4-5 AEs and no treatment-related deaths, and no discernible increase in AEs in the GS+A group when compared with the GS group.ConclusionThe A+GS regimen therapy holds great promise in managing treatment-naive advanced PC, except that future prospective studies with larger sample sizes and multiple centers are required to determine its efficacy and safety.

show abstract

Section: Discussionmentioning

confidence: 99%

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

Zhan

et al. 2023

Front. Endocrinol.

View full text Add to dashboard Cite

show abstract

“…Therefore, anlotinib may play a therapeutic role in a variety of malignancies. Zhang et al revealed that anlotinib inhibited pancreatic cancer cell proliferation and induced its apoptosis (21). Yang et al found that anlotinib had a killing effect on pancreatic cancer cells both in vivo and in vitro (22).…”

Section: Discussionmentioning

confidence: 99%

Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)

Luo

Liao

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Titled the “most destructive of all cancers”, pancreatic cancer is a malignant tumor with a very poor prognosis and has a poor response to systemic therapy. At present, several studies have shown that tegafur-gimeracil-oteracil potassium (hereinafter referred to as TS-1) is no less superior to gemcitabine in the treatment of advanced pancreatic cancer. In addition, a number of current clinical studies have shown that targeted therapy combined with chemotherapy reflects therapeutic advantages in pancreatic cancer. Moreover, in vitro and in vivo experiments have also demonstrated that anlotinib can curb the proliferation of pancreatic cancer cells and induce their apoptosis. Here, we report for the first time that a patient with locally advanced pancreatic cancer achieved good efficacy after switching to TS-1 chemotherapy combined with anlotinib targeted therapy. Previously, the disease of the patient still rapidly progressed without control following the first switch to abraxane combined with gemcitabine chemotherapy (AG regimen) due to the progression after chemo-radiotherapy. In this case, the patient achieved progression-free survival (PFS) of over 14 months via the treatment with anlotinib targeted therapy combined with TS-1 chemotherapy and secondary radiotherapy (prior to secondary radiotherapy, the patient achieved a PFS of nearly 12 months via the treatment with oral anlotinib combined with TS-1). Up to now, the progress of the disease is ceased. The oral administration of targeted therapy and chemotherapy are still in progress and the general condition of the patient is good. This suggests that patients with advanced pancreatic cancer may benefit from treatment with the anlotinib targeted therapy combined with TS-1 chemotherapy.

show abstract

“…Studies have achieved effective results not only in NSCLC and SCLC (10), but also in liver cancer (19,41) or refractory metastatic colorectal cancer (42). There are currently more (15) revealed that anlotinib had a profound inhibitory effect on ribosomes, and regulated the cell cycle, RNA metabolism, and lysosomes as determined by transcriptomics, proteomics, and phosphor proteomics profiling. These studies suggested that anlotinib plus chemotherapy was a feasible regimen for the treatment of PDAC.…”

Section: Discussionmentioning

confidence: 99%

“…PDAC tissues have high expression of VEGF, which is associated with liver metastasis in PDAC and is predictive of poor prognosis (14). Anlotinib exerted noteworthy cytotoxicity on PDAC cells (15). Anlotinib can inhibit proliferation, induce G2/M phase arrest, and trigger apoptosis in PDAC and hepatocellular carcinoma (HCC) cell lines.…”

Section: Introductionmentioning

confidence: 99%

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort

Wu¹,

Huang²,

Zhao³

et al. 2022

Ann Transl Med

View full text Add to dashboard Cite

show abstract

Multi-Omics Analysis of Anlotinib in Pancreatic Cancer and Development of an Anlotinib-Related Prognostic Signature

Cited by 6 publications

References 75 publications

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer

Case Report: A Case of Locally Advanced Pancreatic Cancer Which Achieved Progression Free for Over 12 Months by Subsequent Therapy with Anlotinib Hydrochloride Plus Tegafur-Gimeracil-Oteracil Potassium (TS-1)

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort

Contact Info

Product

Resources

About